参考文章(5)
Jonathan Chambers, Nick Reed, Was Mansoor, Paul Ross, Ashley Grossman, Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3) Regulatory Peptides. ,vol. 164, pp. 6- 7 ,(2010) , 10.1016/J.REGPEP.2010.07.018
Matthew H. Kulke, Emily K. Bergsland, James C. Yao, Glycemic control in patients with insulinoma treated with everolimus. The New England Journal of Medicine. ,vol. 360, pp. 195- 197 ,(2009) , 10.1056/NEJMC0806740
Corinne Bousquet, Julie Guillermet-Guibert, Nathalie Saint-Laurent, Elodie Archer-Lahlou, Frédéric Lopez, Marjorie Fanjul, Audrey Ferrand, Daniel Fourmy, Carole Pichereaux, Bernard Monsarrat, Lucien Pradayrol, Jean-Pierre Estève, Christiane Susini, Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. The EMBO Journal. ,vol. 25, pp. 3943- 3954 ,(2006) , 10.1038/SJ.EMBOJ.7601279
James C Yao, Catherine Lombard-Bohas, Eric Baudin, Larry K Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, Jessica St. Peter, Tomas Haas, David Lebwohl, Eric Van Cutsem, Matthew H Kulke, Timothy J Hobday, Thomas M O'Dorisio, Manisha H Shah, Guillaume Cadiot, Gabriele Luppi, James A Posey, Bertram Wiedenmann, None, Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial Journal of Clinical Oncology. ,vol. 28, pp. 69- 76 ,(2010) , 10.1200/JCO.2009.24.2669
James C Yao, Alexandria Phan, Paulo M Hoff, Helen X Chen, Chusilp Charnsangavej, Sai-Ching J Yeung, Kenneth Hess, Chaan Ng, James L Abbruzzese, Jaffer A Ajani, None, Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b Journal of Clinical Oncology. ,vol. 26, pp. 1316- 1323 ,(2008) , 10.1200/JCO.2007.13.6374